What OliX Pharmaceuticals does

OliX Pharmaceuticals is a clinical-stage Korean biopharmaceutical company developing RNA interference (RNAi) therapeutics built on its proprietary asymmetric siRNA (asiRNA) chemistry and the integrated OASIS platform, which combines asiRNA, cell-penetrating cp-asiRNA, GalNAc-conjugated liver-targeted siRNA, long asiRNA, tripodal siRNA, bulge-structured siRNA, and a dual-targeting OASIS-D format to address the field's core limitations around off-target effects, immune stimulation, and tissue-specific delivery. Founded in 2010 (as BMT, renamed OliX in 2014) and listed on KOSDAQ under ticker 226950 since 2018, the company operates from a Pangyo R&D Center in Seongnam, South Korea, with subsidiaries in San Diego (OliX US Inc. / R&D Lab) and Sydney (OliX AU Pty Ltd) and an mRNA-focused subsidiary (mCureX Therapeutics) at home.

Its pipeline spans dermatology, ophthalmology, metabolic disease, and pulmonary fibrosis: OLX101A (CTGF-targeted, hypertrophic scar, Phase 2a completed in the US), OLX104C (androgen-receptor, androgenetic alopecia, Phase 1b/2a in Australia), OLX301A (MyD88, dry and wet AMD, Phase 1 completed in the US), OLX702A (MASH/obesity, Phase 1 in Australia, globally licensed to Eli Lilly), OLX201A (idiopathic pulmonary fibrosis), and preclinical OLX501A (ALK7, obesity, 2027 IND target). Patented platform technologies are registered across Korea, the US, Europe, Japan, China, and Australia, supporting enforcement against would-be competitors in major markets.

OliX's business model is asset-light and partnership-centric: the company does not sell products directly and instead generates revenue through out-licensing its platform technologies and pipeline candidates to global pharmaceutical partners (notably Eli Lilly for OLX702A cardiometabolic programs worldwide; Hansoh for GalNAc-asiRNA in cardiovascular and metabolic disease across Greater China; and prior deals with Théa for OLX301A/OLX301D and Hugel for OLX101A, both since concluded), supplemented by an emerging consumer-beautics collaboration with L'Oréal spanning hair, skin, and nail applications. Pricing is not publicly disclosed and operates via upfront fees, development and regulatory milestone payments, and royalties on partner sales, with capital formation supported by a KRW 110 billion (~$81M USD) third-party share allotment in June 2026 from BOLD (L'Oréal's CVC) and Weiss Asset Management LP.

Name

OliX Pharmaceuticals

Legal name

OliX Pharmaceuticals, Inc. (올릭스 주식회사)

Website

https://olixpharma.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

OliX Pharmaceuticals is a clinical-stage Korean biopharmaceutical company developing RNA interference (RNAi) therapeutics built on its proprietary asymmetric siRNA (asiRNA) platform for dermatology, ophthalmology, and metabolic disease indications, and licenses its technology and pipeline to global pharmaceutical and cosmetics partners such as Eli Lilly, L'Oréal, and Hansoh Pharma.

Ownership category

akta.pro rank

Product category

RNA interference therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

siRNA Therapeutics (gene silencing) (HLAAADAB)

akta.pro secondary industries

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF)

Keywords

• RNA interference therapeutics
• SiRNA drug development
• Gene silencing technology
• Clinical-stage biopharmaceuticals
• Drug licensing partnerships

Headquarters

HQ city

Suwon

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Technology Licensing and Out-licensing: OliX generates revenue by licensing its proprietary RNAi technologies and pipeline candidates to global pharmaceutical companies. This includes upfront payments, milestone payments tied to development and regulatory achievements, and royalty payments based on product sales.
2. Strategic Investment: The company raises capital through strategic investments from corporate venture capital funds and asset management firms. In June 2026, OliX secured approximately KRW 110 billion (~$81 million USD) through a third-party allotment of newly issued common shares from BOLD (L'Oréal's CVC) and Weiss Asset Management.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

OliX Pharmaceuticals develops RNA interference (RNAi) therapeutics built on its proprietary OASIS platform and asymmetric siRNA (asiRNA) chemistry. The company advances a clinical-stage pipeline of siRNA drug candidates targeting indications in dermatology, ophthalmology, metabolic disease, and rare genetic disorders, while also extending its RNAi platform into consumer cosmetics applications.

Product overview

OliX Pharmaceuticals is a clinical-stage biotech company developing RNAi-based therapeutics through its proprietary OASIS platform. The core technology includes asiRNA, cp-asiRNA (self-delivering), and GalNAc-asiRNA platforms for targeted gene silencing. The company pipeline consists of four main clinical candidates: OLX101A (hypertrophic scars), OLX104C (androgenetic alopecia), OLX301A (age-related macular degeneration), and OLX702A (MASH/obesity), with OLX501A (obesity) in preclinical development. The OASIS platform enables tissue-specific delivery for dermal, ophthalmic, and hepatic applications.

Differentiator

Problem solved

Functional benefit

Brands

• OASIS (OliX Advanced Small Interfering RNA System): Proprietary RNAi platform technology that enhances gene-silencing efficiency and enables tissue-specific delivery
• mCureX Therapeutics

Products and services

• OLX101A siRNA therapeutic candidate targeting connective tissue growth factor (CTGF) for the treatment of hypertrophic scars and related fibrotic skin conditions; designed for patients with pathological scarring.
• OLX104C siRNA-based therapeutic candidate for the treatment of atopic dermatitis, utilizing OASIS-mediated intracellular delivery into keratinocytes.
• OLX301A siRNA therapeutic candidate targeting transforming growth factor beta 2 (TGF-β2) for the treatment of subretinal fibrosis, including complications of neovascular age-related macular degeneration.
• OLX702A GalNAc-conjugated asiRNA candidate targeting INHBE for the treatment of obesity and metabolic diseases, developed in partnership with Eli Lilly.
• OLX501A Preclinical siRNA therapeutic candidate for Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD) targeting the DUX4 gene using OASIS-D delivery technology.
• OASIS Platform Technology Proprietary RNA interference platform technology that enables self-assembly of siRNA strands with improved stability and efficacy, licensed to partners for therapeutic and cosmetic applications.
• cp-asiRNA Platform Cell-penetrating asymmetric siRNA platform technology that enables siRNA delivery into target cells without exogenous carriers, applied across dermatology and cosmetic product development.
• asiRNA Platform Proprietary asymmetric small interfering RNA chemistry platform that improves siRNA specificity and reduces off-target effects, licensed by OliX for therapeutic and partner programs.
• GalNAc-asiRNA Platform GalNAc-conjugated asiRNA platform enabling targeted delivery of siRNA therapeutics to liver hepatocytes, supporting metabolic and rare liver disease programs such as OLX702A.

Quantifiable outcome

• OLX501A (ALK7 target) demonstrated up to 84% ALK7 mRNA knockdown in non-human primate models
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Ten partnerships are on record, tiered core, supporting and strategic.

• L'Oréal GroupecoreStrategic or Co-development Partner · 29 June 2026Pipeline collaboration framework agreement for skin, hair, and nail health applications. Combines OliX's RNAi platform with L'Oréal's beauty science expertise. Includes multiple research programs with potential for cosmetics and innovative beauty products. Expanded from initial 2025 collaboration.
• GaluxesupportingTechnology or Integration · 20 April 2026MOU for joint development of AI-based siRNA delivery platform. Collaboration to leverage artificial intelligence for optimizing siRNA delivery systems.
• Key2Brain ABstrategicTechnology or Integration · 10 February 2026Evaluation and option agreement for TfR-targeted BBB shuttle technology combined with OliX's CNS siRNA candidates. Includes exclusive option for worldwide licensing based on research outcomes. Sweden-based biotech specializing in antibody-based BBB delivery.
• Vect-HorusstrategicTechnology or Integration · 4 February 2026CNS-focused research collaboration using VECTrans BBB shuttle platform combined with OliX's siRNA. Material Transfer and Evaluation Agreement (MTEA) to assess CNS delivery efficacy, target gene knockdown, and tissue distribution. Evaluates potential for treating CNS diseases with RNAi therapeutics.
• Eli Lilly and CompanycoreStrategic or Co-development Partner · 1 February 2025Global licensing and collaboration agreement for OLX702A (MASH/obesity treatment) and cardiometabolic programs. OliX transferred technology for worldwide development and commercialization. Represents a major strategic partnership with one of the world's largest pharmaceutical companies.
• Hansoh Pharmaceuticals Group Co., Ltd.coreStrategic or Co-development Partner · 23 March 2021License and collaboration agreement for GalNAc-asiRNA platform for cardiovascular and metabolic diseases targeting Greater China. Hansoh exercised option for one additional therapeutic candidate (2023). Represents established partnership with leading Chinese pharmaceutical company.
• ThéacoreStrategic or Co-development Partner · 23 March 2019Out-licensing agreement for OLX301A and OLX301D (dry and wet AMD treatment) for EU, Africa, and Middle East. Originally licensed in 2019; agreement expanded in 2021 for worldwide rights excluding Asia-Pacific. Note: Rights for OLX301A/OLX301D were returned to OliX in 2024.
• AM Chemicals LLCsupportingTechnology or IntegrationTechnology introduction agreement for GalNAc technology for liver-targeted siRNA delivery. OliX incorporated this technology into its platform to enable hepatocyte-specific delivery for liver disease therapeutics.
• University of Virginia School of MedicinesupportingStrategic or Co-development PartnerResearch collaboration for OLX301A (dry and wet AMD treatment) development. Combines academic research expertise with OliX's RNAi technology platform.
• Charles River LaboratoriessupportingImplementation/ SI/ Consulting PartnerContract research organization conducting toxicology studies for OLX301A (dry and wet AMD treatment). Provides nonclinical safety assessment services.

Scale indicators4 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Alnylam Pharmaceuticals: Global leader in RNAi therapeutics with approved siRNA products (Onpattro, Givlaari, Oxlumo, Amvuttra). Directly competes with OliX on GalNAc liver-targeted and extrahepatic siRNA delivery and target disease areas (MASH, cardiometabolic).
• Arrowhead Pharmaceuticals: Clinical-stage RNAi company with multiple programs across liver, lung, muscle, and CNS using its own TRiM and GalNAc-based delivery platforms. Closely comparable to OliX in extrahepatic siRNA delivery focus and big-pharma partnership model (e.g., Takeda, Amgen).
• Silence Therapeutics: Clinical-stage RNAi company developing GalNAc-conjugated siRNA for cardiometabolic and rare diseases with a comparable out-licensing/partnership strategy. Directly comparable in target indication space (MASH, cardiovascular) and delivery approach.
• Arcturus Therapeutics: Clinical-stage RNA medicines company developing siRNA and mRNA therapeutics for rare diseases, liver disease, and infectious disease. Comparable in modality (siRNA + mRNA) and clinical-stage profile; OliX's mCureX subsidiary also targets mRNA vaccines.

Broad incumbents

• Ionis Pharmaceuticals: Established leader in antisense oligonucleotide (ASO) therapeutics with multiple approved products (Spinraza, Tegsedi, Waylivra). Comparable as a mature RNA-targeting therapeutics company with broad pipeline, but OliX's siRNA modality and partnership focus distinguish it.
• Novo Nordisk (Dicerna): Acquired Dicerna in 2021 to build an RNAi pipeline targeting MASH, obesity, and cardiometabolic disease — direct overlap with OliX's OLX702A (MASH/obesity) partnered with Eli Lilly. Comparable target disease focus and modality.

Emerging players

• Wave Life Sciences: Clinical-stage RNA therapeutics company using stereopure oligonucleotide chemistry with CNS and liver programs. Comparable in targeting extrahepatic tissues (CNS) and oligonucleotide-platform innovation, though using ASO/RNA editing rather than siRNA.
• Sirnaomics: Clinical-stage RNAi company developing siRNA therapeutics for oncology and fibrotic diseases with operations in the US and China. Comparable modality (siRNA) and Asia-Pacific presence, with overlapping target disease areas (fibrosis).
• Phio Pharmaceuticals: Small clinical-stage RNAi therapeutics company focused on immuno-oncology and skin indications using self-delivering RNAi compounds. Comparable in size and modality focus on local/skin RNAi delivery (Intellitile RNAi technology vs. OliX's cp-asiRNA).
• Benitec Biopharma: Clinical-stage RNAi company developing DNA-directed RNA interference (ddRNAi) therapeutics for oncology and infectious disease, with an ocular program (BBIT) overlapping OliX's ophthalmology focus (OLX301A for AMD).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCEcE8Rqw1aU2XcmG5EPMX6g
• LinkedInlinkedin.com/company/olix
• Xx.com/OliXPharmaceut1

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries4 records

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OliX Pharmaceuticals